Related Experiment Video
Updated: Jan 12, 2026
03:40
Acupoint Catgut Embedding Therapy in Traditional Chinese Medicine for Managing Allergic Rhinitis
Published on: December 20, 2024
1.3K
Comparative Risk for Neuropsychiatric Events in Leukotriene Receptor Antagonist vs. Inhaled Corticosteroid in
Subin Kim1,2, Chang Hoon Han1,2, Junhyuk Chang3
1Department of Biomedical Systems Informatics, Yonsei University College of Medicine, Seoul, South Korea.
Pharmacoepidemiology and Drug Safety
|October 31, 2025
Summary
Leukotriene receptor antagonists (LTRAs) did not show increased neuropsychiatric events (NPEs) in children with asthma compared to inhaled corticosteroids (ICS). This study provides evidence for safer pediatric asthma management.
Area of Science:
- Pediatric Pulmonology
- Pharmacovigilance
- Asthma Management
Background:
- Leukotriene receptor antagonists (LTRAs) are common controller medications for pediatric asthma.
- Concerns exist regarding potential neuropsychiatric adverse reactions (NPEs) with LTRAs.
- Limited direct comparative data on NPE risk between LTRAs and inhaled corticosteroids (ICS) in children.
Purpose of the Study:
- To compare the risk of neuropsychiatric events (NPEs) in pediatric asthma patients treated with LTRAs versus ICS.
- To address inconsistencies in observational study findings regarding LTRA-associated NPEs.
Main Methods:
- Retrospective cohort study using South Korean nationwide claims and multicenter EHR databases (2006-2022).
- Included pediatric asthma patients (5-18 years) initiating LTRA or ICS.
- NPEs assessed within 90 days using diagnostic codes and natural language processing (NLP) on clinical notes; Cox proportional hazards models used.
Main Results:
- Claims data (169,636 LTRA users, 28,845 ICS users) showed no significant difference in NPE risk (calibrated HR, 1.14 [95% CI, 0.92-1.42]).
- EHR data (1,641 LTRA users, 1,607 ICS users) using NLP analysis yielded consistent results (calibrated HR, 1.33 [95% CI, 0.66-2.68]).
Conclusions:
- LTRA use is not associated with a significantly increased risk of neuropsychiatric events in children with asthma.
- Findings support informed clinical decision-making for pediatric asthma treatment strategies.
Related Concept Videos
01:19Antiasthma Drugs: Leukotriene Modifiers
1.7K
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
1.7K
01:25Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids
1.5K
Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
1.5K
01:26Asthma-II: Pathophysiology and Classification
4.1K
Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
4.1K
01:30Asthma-IV: Diagnostic and Management
3.1K
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
3.1K
01:20Asthma: Pathogenesis and Management
1.2K
Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
1.2K
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
1.7K
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
1.7K